Écrit par novozymes | 31 Janvier 2013

Novozymes acquires Iogen Bio-Products, industrial enzyme business of Ottawa-based Iogen Corporation for CAD 67.5 million (approximately DKK 370 million) and potential earn-out payments of up to CAD 12.5 million (approximately DKK 70 million). The deal provides Novozymes with all commercial rights to Iogen Bio-Products’ existing product portfolio, pipeline, facilities and know-how...

Écrit par EMBO | 30 Janvier 2013

30 January 2013 – The Federation of European Biochemical Societies (FEBS), EMBO, and the French Society for Biochemistry and Molecular Biology will hold a joint conference for the life sciences in 2014. The FEBS–EMBO 2014 Conference will take place from the 30 August to 4 September at the Palais des Congrès in Paris, France.

The FEBS–EMBO 2014 Conference will be a unique...

Écrit par EMBO | 22 Janvier 2013

The 2013 LOUIS-JEANTET PRIZE FOR MEDICINE is awarded to the geneticist, Michael Stratton, director of the Wellcome Trust Sanger Institute in Cambridge, and jointly to the German biochemists Peter Hegemann, researcher at the Department of Experimental Biophysics at the Humboldt University, Berlin, and Georg Nagel, researcher at the Institute Julius-von-Sachs at the Biocenter, University...

Écrit par Novozymes | 21 Janvier 2013

COPENHAGEN, DENMARK – January 21, 2013 - Novozymes, the world leader in bioinnovation and industrial enzymes, today reported 7% sales growth in 2012 compared with 2011. EBIT increased by 17%, raising the EBIT margin to 24.4%. Net profit grew by 10%. Strong free cash flow before acquisitions of DKK 1,581 million exceeded the outlook. For 2013, the EBIT margin is expected to remain at its...